Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Democratic Leaders Question CMS Charges For ACA Outreach-Targeted User Fees

Executive Summary

Chairs of Democratic-controlled health committees in the US House, and Democrats serving as ranking members of US Senate health panels, sent a letter to the Centers for Medicare and Medicaid Services and the Department of Health and Human Services last week questioning the agencies’ expenditures of user-fee funds intended to support outreach activities under the Affordable Care Act, which the Trump administration opposes.

You may also be interested in...



Newly Elected Dems Will Defend Preexisting Conditions, May Fight Device Tax Repeal

Experts predicted continuing fights over insurance protections for preexisting conditions, and that newly elected Democrats may oppose device tax repeal in 2019 and 2020, due to the potential loss of federal revenue to pay for expanded health care coverage.

Kavanaugh’s Potential Rulings On ACA’s 10 Essential Benefits Could Impact Medtech Coverage

An analysis of Supreme Court nominee Brett Kavanaugh’s prior rulings opposing the Affordable Care Act, and how his weight on ACA cases coming before the high court may remove some marketplace insurance for medtech products for preexisting illnesses and mental health that are currently covered.

The third of a multi-part Medtech Insight feature series on what a more conservative Supreme Court could mean for future court decisions that impact the medical device industry.

FDA Commissioner Nominee Hahn Advances To Full Senate, Despite Some Dems’ Reservations

Stephen Hahn, the Trump administration’s nominee to lead the US FDA, has been approved by the Senate Health, Education, Labor and Pensions (HELP) Committee, with some “no votes” from Democratic senators in leadership positions, and is expected to be considered by the full Senate this week.

Topics

UsernamePublicRestriction

Register

MT124496

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel